Alpha Profiles · Company Profile

Adagene Inc.

https://registry.alpha.ac/companies/adagene-inc

Entity: Public listing published
Primary listing: NASDAQ: ADAG
Verification: Partially verified
Last reviewed: 2026-09-12T21:32:05.800844+00:00

Overview

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for indi

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

11 public records

Alexander Goergen

Vice President, Head of Business Development

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Guizhong Liu, Ph.D.

Senior Vice President of Early Drug Discovery

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Jiping Zha

Executive Vice President of Clinical Development

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Man Kin (Raymond) Tam, M.B.A., B. Eng.

Chief Financial Officer and Director

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Mickael Chane-Du

Chief Strategy Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Peter Luo, Ph.D

Co-Founder, Chief Executive Officer, President of R&D, and Chairman of the Board

Board chairIndependence not stated

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Qinghai Zhao, Ph.D

Chief Manufacturing Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Songmao Zheng, Ph.D.

Senior Vice President of Clinical Pharmacology and Quantitative Sciences

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Wenlin Zeng

Vice President of Early Stage CMC

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Xiaohong (Kristine) She

Senior Vice President, Head of Clinical Operations

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Yan Li, M.B.A.

Senior Vice President, Bioinformatics and Information Technology

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-038612Apr 1, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 12, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.